December 3, 2006 -- The Centient Biotech 200™ ended the week with a net loss of 38 points at 3947, a drop of almost 1%. Breadth was negative for the week. The IPO market is starting to shake off its Thanksgiving holiday somnolence, with Affymax and Artes Medical scheduled for one week out. On Saturday, Pfizer announced it would abandon its highly anticipated cholesterol drug torcetrapib. Analysts predict that Pfizer could drop between 5% and 25% on the news. On a more mundane level, tiny Targeted Genetics soared as traders bid the stock higher; Genomic Health gained after Aetna agreed to underwrite the cost of its breast cancer test; BioSante Pharma rose in front of the PDUFA for its estradiol transdermal gel; Dynavax shot up after releasing positive Phase III data for its hepatitis B vaccine; and Memory Pharma gained after completing enrollment in a trial for bipolar disorder. More details...
